Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncology Pharma Inc ONPH

Healthcare Biotechnology
Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals... see more

Recent & Breaking News (GREY:ONPH)

Oncology Pharma Announces the Appointment Of New Chief Financial Officer

GlobeNewswire January 28, 2021

Oncology Pharma Announces Extension of Letter of Intent with Kalos Therapeutics, Retained an Interim CEO and Approval of Reverse Stock Split

GlobeNewswire August 27, 2020

Oncology Pharma Licensor and Co-Development Partner, Kalos Therapeutics, Announces Progress in Covid-19 Preventative & Therapeutic Approaches

Accesswire April 21, 2020

Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19

GlobeNewswire April 6, 2020

Oncology Pharma Continues Licensing Agreement with NanoSmart

GlobeNewswire March 11, 2020

Oncology Pharma, Inc. Narrows Focus on Funding Efforts

GlobeNewswire January 28, 2020

CORRECTION: Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd

GlobeNewswire December 26, 2019

Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Partners Ltd

GlobeNewswire December 23, 2019

Oncology Pharma Signs Letter of Intent to Acquire a Significant Stake in Diagnomics, Inc.

GlobeNewswire December 11, 2019

Oncology Pharma and Ribera Solutions Signed a Licensing Agreement for the Use of Ribera's Clinical Trials Platform, Connect2Med

GlobeNewswire November 6, 2019

Oncology Pharma Appoints Dr. Vijay Mahant as the Chief Scientific Officer and Chief Operating Officer

GlobeNewswire October 15, 2019

Oncology Pharma Elects Dr. Stefan Gruenwald (MD, PhD) to its Board of Directors

GlobeNewswire October 8, 2019

Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals, Inc., Combination Therapy Offers the Potential of a Safer and More Effective Approach to a Wide Variety of Cancer Treatments

GlobeNewswire September 30, 2019

Update: Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide License and Co-Development of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

GlobeNewswire August 19, 2019

Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide Licence and Co-Devlopent of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

GlobeNewswire August 19, 2019

Oncology Pharma Appoints Stefan Gruenwald (MD. Ph.D) as an Advisor on its Advisory Board

GlobeNewswire July 15, 2019

SourcingLink.net Announces Corporate Name Change to Oncology Pharma, Inc.

GlobeNewswire June 17, 2019

Veterinary Oncology Licensing Agreement Signed Between SourcingLink.net and NanoSmart Pharmaceuticals, Inc.

GlobeNewswire April 3, 2019

SourcingLink.net Enters into an Exclusive Worldwide Licensing Agreement with NanoSmart Pharmaceuticals for Anti-Nuclear Antibody (ANA)-Targeted Doxorubicin Formulations to Treat Cancer

GlobeNewswire March 25, 2019

SourcingLink.net Signs a Letter of Intent with NanoSmart Pharmaceuticals, Inc. for a Licensee and Co-Development Collaboration of NanoSmart's Proprietary Targeted Drug Delivery System for Cancer Drugs

GlobeNewswire February 26, 2019